IDEXX raises its 2026 EPS outlook as recurring diagnostics growth, wider margins and international expansion offset softer U.S. veterinary traffic.

ABT's Medical Devices growth is fueled by electrophysiology, expanding CGM adoption and a cardiovascular pipeline extending into 2029 and beyond.

QuidelOrtho's 2026 outlook cut highlights deeper China and respiratory risks, while cash use and rising debt add pressure despite resilient core growth.

QuidelOrtho's resilient core growth and $50 million cost plan offer support, but China weakness, cash use and heavy debt keep the near-term case cautious.

QuidelOrtho's 31.7% three-month rally meets resilient core growth and cost savings, but China weakness, lower guidance and high debt cloud further gains.

Edwards Lifesciences pairs accelerating structural heart growth and stronger leverage with a premium valuation that leaves less room for execution setbacks.

ABT's EPD growth is fueled by emerging-market strength, broad branded generics and healthcare demand, with biosimilars adding opportunities.

DexCom's broader CGM coverage, G7 15 Day rollout and rising margins support growth, but premium valuation, competition and litigation temper upside.

DXCM's 2026 rebound is backed by stronger growth, G7 15 Day adoption and broader CGM access, but competition and reimbursement remain key risks.

DexCom's 52.5% three-month rally is backed by earnings growth and margin gains, but premium valuation, competition and litigation raise the bar.